Lindsay leads the federal affairs practice and represents her clients' interests with Congress, federal agencies, the presidential administration and the government affairs community. Lindsay's in-depth knowledge enables her to excel at navigating the complexities of Washington for clients.
Located in:
Areas of Focus:
Lindsay represents and advises Fortune 500 companies, universities, health care companies, nonprofits and trade associations on federal relations. She covers a range of legislative, policy and regulatory issues so that she may advise her clients and act on their behalf with the federal government. She has extensive knowledge in numerous areas, including electronic health records, Medicare and Medicaid, agriculture, public health, veterans' affairs, higher education, food safety, financial services and technology, federal appropriations, and various regulatory matters coming out of federal agencies.
Having worked for fifteen years in Washington, Lindsay has developed a stellar reputation with policymakers, congressional staff and federal officials, who in turn work closely with her clients on the issues that matter to them. Understanding her clients' needs allows Lindsay to become a brand ambassador and communicator on clients' behalf. As an experienced government relations professional, she excels at developing and executing a unique strategy for each client.
As part of her full range of services, Lindsay:
Before joining the firm, Lindsay spent six years on Capitol Hill as a senior legislative staffer, where she managed a diverse legislative portfolio. In 2010, she joined a government affairs practice, where she represented defense, university and health care clients with the federal government.
Press Coverage
10.13.23
Troutman Pepper Strategies Working to Increase Clinical Trial Diversity
Articles + Publications
11.09.22
2022 Midterm Election Results: Update 11/09/22
Articles + Publications
11.01.22
2022 Midterm Election
Tobacco Law Blog
07.06.21
Tobacco in the 117th Congress
Firm Events
03.23.21
COVID-19: A Year Later. Where Do We Go From Here?